USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Korea Research Institute OF Bioscience AND Biotechnology

USPTO PatentsView assignee record - 168 granted patents across 53 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

RSS updates for this company

The verdict

According to USPTO PatentsView, Korea ranks #2,330 of 49,997 tracked US assignees by granted-patent volume, with 168 patents across 53 technology areas.

#2,330
of 49,997 US assignees by volume
Top 12%
by Innovation Score (50.8/100)
9.3
avg claims per patent
-71%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R2330 · Foreign Corporation #2,330 · 168 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MID 168 grants
  • TOP-DECILE #2,330/49,997
  • PHOTO-FINISH Extreme Networks
  • CPC-WIDE A61K · 53 areas
  • INNOV-PAR 50.8/100
  • CLAIMS-PAR 9.3 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DROP -71% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Extreme Networks, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Korea

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Korea's Innovation Score is 50.8/100 (top 12% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

How Korea's grant cadence moved

Between 2020–2024, Korea Research Institute OF Bioscience AND Biotechnology received 35 grants versus 119 in 2015–2019 (-71% equal-window velocity, below median growth). Across complete PatentsView years, output peaked in 2015 at 29 grants and bottomed in 2022 at 4. Lead class A61K accounts for 54.8% of the portfolio across 53 subclasses. Volume neighbours: Extreme Networks, Inc. (#2,326) and Oerlikon Surface Solutions AG, Pfäffikon (#2,334).

Korea's three-year grant acceleration

From 2019–2021 to 2022–2024, Korea Research Institute OF Bioscience AND Biotechnology moved from 38 to 14 grants (0.37x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,918. See the growth leaderboard.

Who files at Korea's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Korea holds 168 patents at rank #2,330, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Korea

By rank, the assignees closest to #2,330 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Korea's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Korea, neither rank-band nor same-CPC leaders (those blocks stay above).

Korea's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

51 Top 12% higher than 88% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

010203040 20152016201720182019202020212022202320242025 14
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Korea Research Institute OF Bioscience AND Biotechnology patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 29 17.3%
2016 26 15.5%
2017 26 15.5%
2018 21 12.5%
2019 17 10.1%
2020 13 7.7%
2021 8 4.8%
2022 4 2.4%
2023 5 3.0%
2024 5 3.0%
2025partial year 14 8.3%

Which technologies does Korea Research Institute OF Bioscience AND Biotechnology patent most?

Top 15 of 53 technology areas

Where it ranks

Overall rank by patents

#2,330

of 49,997 tracked assignees

Innovation Score

50.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Korea Research Institute OF Bioscience AND Biotechnology's patent record in context - here's where to go next.

  • Korea Research Institute OF Bioscience AND Biotechnology's lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 54.8% of its portfolio - see every assignee active in that class. Explore A61K
  • Ranked #2,330 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Korea Research Institute OF Bioscience AND Biotechnology against Extreme Networks, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 50.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.